10-Q: BioScience Health Innovations Q1 2026 Results Show Revenue Dip, Focus on New Products

BioScience Health Innovations Inc. reported a net loss for the first quarter of 2026, with revenues declining year-over-year, attributed to sales channel adjustments and a rescheduled major order, while advancing its patent-pending product pipeline.

Summary

• BioScience Health Innovations Inc. reported a net loss of $229,907 for the three months ended March 31, 2026, a shift from a net income of $426,798 in the same period of 2025.
• Revenue for the first quarter of 2026 was $750,946, down from $1,227,070 in the first quarter of 2025, due to adjustments in sales channels and a rescheduled large customer order.
• Operating expenses increased, with general and administrative expenses rising to $625,809 from $433,561 and consulting fees increasing to $89,694 from $35,786, partly due to efforts to move to a senior exchange and accounting system upgrades.
• The company's cash balance stood at $1,145,005 as of March 31, 2026, with net working capital of $1,549,089, which management believes is sufficient for the next year.
• Cash used in operating activities was $552,107 for the quarter, compared to cash provided by operating activities of $328,309 in the prior year's quarter.
• Financing activities provided $1,035,187 in net cash, primarily from advances from related parties and proceeds from common stock sales, while $150,000 was repaid to related parties.
• The company is pursuing a private placement to raise up to $1,000,000 and plans to file a Form 1-A with the SEC.
• Key strategic focuses include patent-pending Methylene Blue products and specialty offerings targeting markets such as dementia, ADHD, Long Covid, and weight loss, leveraging growing interest in mitochondrial health.
• The company is advancing its proprietary MODS Max platform for enhanced bioavailability of peptides and nutrients, with a focus on testosterone optimization and NAD+ cellular health products.
• A significant development is the expected reclassification of certain peptides from FDA Category 2 to Category 1, which would allow for their compounding by 503A pharmacies, directly benefiting BHIC's product lines and platform strategy.
• The company identified material weaknesses in its internal control over financial reporting, including a lack of sufficient accounting resources and segregation of duties, and plans to address these upon raising sufficient capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reported net loss, declining revenues, and increased operating expenses, despite positive developments in the product pipeline and strategic initiatives.

Positives

• Advancement of patent-pending Methylene Blue products and specialty offerings targeting significant health markets.
• Development of the proprietary MODS Max platform for enhanced bioavailability of peptides and nutrients.
• Anticipated FDA reclassification of key peptides to Category 1, creating new commercial opportunities for oral peptide products.
• Strong cash position of $1,145,005 as of March 31, 2026, with sufficient working capital for the next year.
• Successful issuance of 437,067 shares of common stock for cash proceeds of $437,067 during the quarter.
• Positive cash flow from financing activities totaling $1,035,187, indicating access to capital.
• Management expresses optimism and confidence in reaching projected year-over-year growth.
• The company is actively exploring partnerships and strategic alliances to maximize stakeholder value.
• Internal fulfillment operations are highlighted as a component of customer experience and a competitive differentiator.

Negatives

• Net loss of $229,907 for the quarter, compared to a net income in the prior year.
• Revenue decreased to $750,946 from $1,227,070 year-over-year.
• Significant increase in general and administrative expenses to $625,809 from $433,561.
• Consulting fees more than doubled to $89,694 from $35,786.
• Negative cash flow from operating activities of $552,107 for the quarter.
• A significant customer order was rescheduled to the second quarter, impacting current period revenue.
• Material weaknesses identified in internal control over financial reporting, including insufficient accounting resources and lack of segregation of duties.

Risks

• The company's ability to successfully raise capital through its private placement and subsequent Form 1-A filing is critical for future operations and addressing internal control weaknesses.
• The rescheduling of a major customer order highlights potential revenue volatility and reliance on specific large deals.
• The company's reliance on related party transactions for financing, although structured with a promissory note, warrants ongoing monitoring.
• The effectiveness of the company's strategy to transition to a senior exchange is subject to regulatory and market conditions.
• The company has not implemented specific cybersecurity policies, although it recognizes the importance of developing such measures.
• The success of new product launches and market penetration for Methylene Blue and other specialty offerings is subject to market acceptance and competitive pressures.
• The company's financial statements are prepared assuming it can continue as a going concern, but significant operating losses and negative cash flows from operations present a risk if future funding is not secured.

Future Outlook

Management expresses optimism about carving out profitable positions in the marketplace through patent-pending Methylene Blue products and other specialty offerings, targeting markets such as dementia, ADHD, Long Covid, and weight loss. The company believes it is well-positioned to capitalize on market opportunities with adequate capital infusion. Management is confident in reaching projected year-over-year growth and plans to focus on gaining traction for its mental health and general wellness products.

Management Comments

• "As a leadership team we are optimistic and excited about our opportunities to carve out very profitable positions in the marketplace through our patent-pending Methylene Blue products along with our additional specialty product offerings."
• "The market opportunities we are targeting includes: Dementia and Alzheimers disease, ADHD and ADD, Long Covid, General Energy, Traumatic Brain Injury, Mild Cognitive Decline, GLP-1 Weight Loss, Sleep Improvement, Epilepsy and Seizure Reduction and Nasal Health and Allergy."
• "A trend that we believe is very beneficial and encouraging is the recent growing interest in mitochondria health and the role that mitochondria dysfunction plays in mental health and physical health issues. Methylene Blue and specialty natural options has emerged as valuable foundational health options on these fronts."
• "We believe we are very well positioned and with adequate capital infusion we will be able to capitalize on multiple market opportunities."
• "Management is still confident in reaching the projected year over year growth."
• "Management believes that its cash balance of $1,145,005 as of March 31, 2026 is sufficient to meet its obligations over the next year."
• "Leadership is actively exploring partnerships and strategic alliances to maximize value for stakeholders."
• "Management is actively working to strengthen leadership by adding two independent directors prior to a Nasdaq uplist."

Industry Context

StockSavvy.ai notes that BioScience Health Innovations is operating in the rapidly growing health and wellness sector, with a particular focus on supplements and nutraceuticals targeting mental health, cognitive function, and cellular optimization. The company's strategy leverages emerging scientific interest in areas like mitochondrial health and the potential of compounds like Methylene Blue. The anticipated FDA reclassification of certain peptides is a significant industry development that could unlock substantial market opportunities for companies with advanced delivery platforms like BHIC's MODS Max.

Comparison to Industry Standards

• The company's NAD+ market opportunity is compared to NAGE (ChromaDex), which has a market cap of $390-$812 million and approximately 90 patents. The NAD+ market is projected to grow from $5.6 billion in 2025 to $11.7 billion by 2030.
• The Testosterone Replacement Therapy (TRT) market is valued at $2.1 billion in 2026 and projected to reach $2.6 billion by 2031. BHIC's flagship product, TPrime365, targets this market.
• The GLP-1 market is projected at $130 billion by 2030, a market that BHIC's peptide products, particularly the GLOW Recover Peptide, are positioned to intersect with.
• Comparable transactions in peptide delivery include Merck's acquisition of Cyprumed for $493 million and LCatterton's acquisition of Thorne for $680 million, indicating significant investor interest in this space.
• The company's focus on mitochondrial health aligns with a growing trend in the broader health and wellness industry, where companies are increasingly investing in research and products related to cellular energy and aging.

Corporate Governance

Legal Proceedings

• Management is not aware of any legal proceedings contemplated by any governmental authority or any other party involving the company or its properties.
• No director, officer, or affiliate is a party adverse to the company in any legal proceeding or has an adverse interest to the company in any legal proceedings.

Related Party Transactions

• During the three months ended March 31, 2026, the company purchased $745,060 worth of inventory from Ageless Holdings, LLC (owned by management/board members).
• During the three months ended March 31, 2026, the company received $3,059 in advances from Ageless Holdings, LLC and repaid $150,000.
• During the three months ended March 31, 2025, the company purchased $456,556 worth of inventory from Ageless Holdings, LLC.
• During the three months ended March 31, 2025, the company received $132,960 in advances from Ageless Holdings, LLC and repaid $522,000.
• On March 28, 2026, a settlement agreement was finalized with Ageless Holdings, LLC, resulting in a promissory note for $460,402, carrying a 7% annual interest rate and maturing on December 31, 2026.

Stakeholder Impact

• Shareholders: The net loss and revenue decline may negatively impact shareholder value in the short term, while the strategic focus on new products and potential capital raise could offer future upside.
• Creditors: The company's liquidity position and net working capital appear sufficient for the next year, but ongoing operational losses and reliance on financing could be a concern.
• Employees: Increased administrative expenses may indicate growth in operational staff, but the company's financial performance could impact job security.
• Suppliers: The company continues to purchase inventory from a related party, Ageless Holdings, LLC, indicating a continued relationship that may impact other supplier relationships.

Next Steps

• Complete the private placement to raise up to $1,000,000.
• Prepare and file Form 1-A with the SEC.
• Focus on gaining traction for mental health and general wellness products.
• Continue to develop and commercialize patent-pending Methylene Blue products and other specialty offerings.
• Strengthen leadership by adding two independent directors prior to a Nasdaq uplist.
• Address material weaknesses in internal control over financial reporting by establishing written policies and hiring additional accounting personnel once sufficient capital is raised.
• Continue investing in fulfillment infrastructure, staffing, and process improvements at the Bluffdale location.
• Evaluate strategic partnerships or acquisitions that align with the company's vision.

Key Dates

Recommendation

The company shows promising developments in its product pipeline, particularly with its peptide delivery platform and Methylene Blue products, and the potential impact of FDA reclassifications is significant. However, the current financial performance, marked by a net loss, declining revenue, and identified material weaknesses in internal controls, presents considerable risk. The planned capital raise is crucial for addressing these weaknesses and funding growth. A 'hold' recommendation reflects the balance between speculative upside from strategic initiatives and the immediate financial and control concerns.

Keywords

BioScience Health Innovations, SEC Filing, 10-Q, Quarterly Report, Financial Statements, Results of Operations, Liquidity, Methylene Blue, Peptide Delivery, MODS Max, Nutraceuticals, Health and Wellness, Private Placement, Internal Controls, Biotech